Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613413 · ClinicalTrials.gov registry record · Phase 2
A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)
A Phase 2 study of Metastatic Squamous Non-Small Cell Lung Carcinoma, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05613413 is a Phase 2 study of Metastatic Squamous Non-Small Cell Lung Carcinoma that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05613413, a Phase 2 study of Metastatic Squamous Non-Small Cell Lung Carcinoma, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study to assess the efficacy, safety, and Health Related Quality of Life (HRQoL) of combination cabozantinib and pembrolizumab as maintenance therapy for patients with metastatic squamous Non Small Cell Lung Cancer(sqNSCLC) who have received 4 cycles of induction therapy with pembrolizumab, carboplatin, and nab-paclitaxel or paclitaxel.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cabozantinib
- DRUG Pacliltaxel or Nab-paclitaxel
- DRUG Carboplatin or Cisplatin
Study Locations (1)
Illinois
- Ryan Nguyen - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05613413
The ClinicalTrials.gov registry entry for NCT05613413 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Squamous Non-Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05613413 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05613413 about?
NCT05613413 is a clinical study titled "A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)". This is a phase II study to assess the efficacy, safety, and Health Related Quality of Life (HRQoL) of combination cabozantinib and pembrolizumab as maintenance therapy for patients with metastatic squamous Non Small Cell Lung Cancer(sqNSCLC) who have received 4 cycles of induction therapy with pemb...
What is the current status of trial NCT05613413?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-12-28. Estimated completion is 2028-09.
What conditions does trial NCT05613413 study?
This clinical trial studies the following conditions: Metastatic Squamous Non-Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT05613413?
The interventions under investigation include: Pembrolizumab (DRUG), Cabozantinib (DRUG), Pacliltaxel or Nab-paclitaxel (DRUG), Carboplatin or Cisplatin (DRUG).
Who is sponsoring clinical trial NCT05613413?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05613413 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Squamous Non-Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.